About eton pharmaceuticals inc - ETON
Eton Pharmaceuticals, Inc. engages in the development, acquisition, and commercialization of prescription drug products. Its products include Biorphen, Alaway Preservative Free, zonisamide oral suspension, topiramate oral suspension, lamotrigine for oral suspension, cysteine injection, and ephedrine ready-to-use injection. The company was founded in April 2017 and is headquartered in Deer Park, IL.
ETON At a Glance
Eton Pharmaceuticals, Inc.
21925 West Field Parkway
Deer Park, Illinois 60010-7278
| Phone | 1-847-787-7361 | Revenue | 79.95M | |
| Industry | Pharmaceuticals: Major | Net Income | -4,601,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 104.942% | |
| Fiscal Year-end | 12 / 2026 | Employees | 44 | |
| View SEC Filings |
ETON Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 5.691 |
| Price to Book Ratio | 17.487 |
| Price to Cash Flow Ratio | 43.24 |
| Enterprise Value to EBITDA | 111.796 |
| Enterprise Value to Sales | 5.755 |
| Total Debt to Enterprise Value | 0.068 |
ETON Efficiency
| Revenue/Employee | 1,817,045.455 |
| Income Per Employee | -104,568.182 |
| Receivables Turnover | 6.80 |
| Total Asset Turnover | 0.95 |
ETON Liquidity
| Current Ratio | 1.574 |
| Quick Ratio | 1.173 |
| Cash Ratio | 0.674 |
ETON Profitability
| Gross Margin | 53.458 |
| Operating Margin | 0.09 |
| Pretax Margin | -5.701 |
| Net Margin | -5.755 |
| Return on Assets | -5.47 |
| Return on Equity | -18.192 |
| Return on Total Capital | -8.039 |
| Return on Invested Capital | -8.958 |
ETON Capital Structure
| Total Debt to Total Equity | 118.846 |
| Total Debt to Total Capital | 54.306 |
| Total Debt to Total Assets | 33.744 |
| Long-Term Debt to Equity | 84.993 |
| Long-Term Debt to Total Capital | 38.837 |